Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report H1 2024: Revenue growth in all verticals

COMPANY ANNOUNCEMENT NO. 105 Interim financial report for Q2 and H1 2024Today, LED iBond International’s (LED iBond) Board of Directors approved the interim report for the second quarter (Q2) and first half (H1) of 2024. Martin Løbel, CEO of LED iBond International, comments: “LED iBond continued its revenue growth in Q2 and H1. In H1, we have delivered several lighting solutions for solar carport projects in Austria and the UK. We have also delivered our HORTISABER™ lighting solution to one of the largest green house facilities in DK as well as a GRACY™ vertical farming solution to a

Dicot Pharma's study results selected for the largest sexual medicine conference in the US and publication in The Journal of Sexual Medicine

Uppsala, Sweden, August 20, 2024. It is now confirmed that Dicot Pharma's in-depth clinical results will be presented at the largest conference in sexual medicine in the United States, which will be held in October 2024 in Arizona. The speaker is the American sexual medicine expert Dr Harin Padma-Nathan. The results will also be published in the scientific journal The Journal of Sexual Medicine.The company has earlier communicated, at the completion of the statistical analysis for the phase 1 clinical data, that it was decided that the results should be published through an abstract. The

SENS publishes interim report for the period April – June 2024

Sustainable Energy Solutions Sweden Holding AB (”SENS” or the ”Company”) hereby publishes the interim report for the period April – June 2024. The full report is available in Swedish on SENS's website www.sens.se and as an attached file.2024-04-01 – 2024-06-30 (second quarter) · Net sales amounted to 15 925 kSEK (1,727). Adjusted net sales including results from shares in group companies amounted to 27,345 kSEK (6,176). · Operating profit (EBIT) amounted to 5,470 kSEK (-5,252). Adjusted EBIT including results from shares in group companies amounted to 16,890 kSEK (-804). ·

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 180 – 20 AUGUST 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Martin Badsted, Chief Financial Officer, tel.: +45 33 42 05 26, e-mail: mba@norden.com

Multiconsult ASA – Status on share buy-back

Multiconsult ASA (OSE: MULTI) announced on 3 June 2024 a non-discretionary agreement with DNB Markets, a part of DNB Bank ASA for the repurchase of up to 500 000 of its ordinary shares in the market with employee share saving programme and executive management bonus schemes.From 9 – 19 August 2024, Multiconsult ASA has purchased a total of 22 049 own shares at Oslo Børs at an average price of NOK 168.5210 per share.  Aggregated overview of transactions per day: Overview oftransactionsDate Aggregated daily Weighted average Total daily volume (number

Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator

Key highlights Lundbeck’s total revenue grew by +10% CER[1] (+8% DKK) to DKK 10,741 million in the first six months of 2024, with all regions contributing to growth · United States: DKK 5,307 million (+11% CER; +11% DKK) · Europe: DKK 2,517 million (+10% CER; +8% DKK) · International Markets: DKK 2,795 million (+8% CER; +2% DKK) The revenue of Lundbeck’s strategic brands increased by +19% CER (+18% DKK), reaching DKK 7,799 million, representing 73% of total revenue · Rexulti®: DKK 2,381 million (+13% CER; +12% DKK) · Brintellix®/Trintellix®: DKK 2,351 million (+11%

Bluefors Launches XLDHe High Power System for 1 K Experiments

Bluefors today announced the immediate availability of a XLDHe High Power System – a cryogen-free, helium-4 powered measurement system that delivers extremely high cooling power for experiments in the 1 K temperature range. The XLDHehp is ideal for demanding applications such as spin qubit quantum computing devices, or single photon detectors for photonic quantum computers.The XLDHehp gives users the flexibility and power needed to scale up experiments. The system generates extremely high cooling power between 200-700 mW at 1–1.2 K and features side-loading ports for fast exchange of

MilDef wins additional orders from BAE Systems Bofors worth 18 MSEK

Following the 10-year framework agreement with BAE Systems Bofors signed in February and the order of SEK 52 million communicated in April, another additional order has been signed for IT equipment for the Archer artillery system. The orders include computers and switches worth SEK 18 million. Deliveries will start in 2024.The orders now won are a natural continuation of the cooperation and concern additional orders for IT equipment for the toughest conditions and most challenging environments, which prevent information from being interrupted, intercepted or disrupted. “These additional

Hexagon Composites’ net zero targets validated by the Science Based Target initiative

20 August 2024: Hexagon Composites (OSE: HEX.OL), world leader in composite cylinder technology and systems for storage and transportation of clean gaseous energy, has committed to being net zero by 2050. In July 2024, Hexagon’s net zero targets were validated by the Science Based Target initiative (SBTi). The SBTi defines and promotes best practice in science-based target setting, and independently assesses and approves companies’ targets. Being a provider of solutions that help fleets and OEM’s transition to low-carbon and carbon negative solutions, Hexagon recognizes the importance of

MCF acted as exclusive financial advisor to Comitis Capital on its acquisition of The Tofoo Co.

MCF is pleased to announce that it has acted as exclusive financial advisor to Comitis Capital, a European private equity investor headquartered in Frankfurt, Germany, on its acquisition of The Tofoo Co. (“TTC”), the UK market leader in tofu products, from its management team and leading miso producer, Hikari Miso. MCF provided buy-side M&A advisory services and facilitated the transaction through our strong relationships with the selling shareholders.The Deal The transaction sees Comitis Capital enter as the new owner. The new partnership will enable The Tofoo Co. to further strengthen

Lundbeck raises financial guidance for 2024

Valby, Denmark, August 20, 2024 - H. Lundbeck A/S (Lundbeck) announced revenue and adjusted EBITDA growth at constant exchange rates (CER) for the first six months of 2024 and that the full year revenue and adjusted EBITDA outlook at CER have been raised. In the second quarter of 2024, Lundbeck’s revenue increased by 13% and adjusted EBITDA increased by 14% both at CER. Key figures Growth (CER) H1 2024 Q2 2024Revenue 10% 13%EBITDA 9% 17%Adjusted EBITDA 5% 14% The sales outlook for 2024 is updated, primarily reflecting

Nightingale Health attains UKCA marking for its blood analysis technology to bring its technology to healthcare use in the United Kingdom

Nightingale Health Plc Press release 20 August 2024 at 9:45 a.m. (EEST)   Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health, has attained UKCA (UK Conformity Assessed) marking under the UK Medical Devices Regulations. Nightingale Health has already been working for years with many leading universities in the UK and the technology is being used by many landmark health initiatives, such as the UK Biobank, to profile their entire sample collections.  To expand its activities in the UK, Nightingale Health has established

Axfood enters into agreement with Linas Matkasse and closes down Middagsfrid

Due to weak market development for pre-planned subscribed meal kits, Axfood has made the decision to close downs its meal kit company Middagsfrid as of the last day in September, and make use of the value Middagsfrid has created in other ways. In conjunction with closing down the operations, an agreement is entered into with Linas Matkasse around cooperation to continue to offer the customers of Middagsfrid meal kits to their homes.Middagsfrid was established in 2007 and was first to offer home delivery of pre-planned subscribed meal kits. Axfood acquired Middagsfrid in 2017 to further

Interim report January – June 2024

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value at the end of the period was SEK 198 per share compared with SEK 198 per share at the start of the year, which is an increase of 1.8 per cent adjusted for dividends. The benchmark index (SIXRX) rose 10.6 per cent. The net asset value at 19 August was SEK 204 per share.[1] · The total return on the Latour share was 10.7 per cent measured against the SIXRX, which increased 10.6 per cent. INDUSTRIAL OPERATIONS The second quarter · The industrial operations’ order intake rose 7 per cent to SEK 6,570 m (6,128 m), a 5

Nordea Bank Abp flagging notification: Norges Bank’s shareholding decreases below threshold of five percent

Nordea Bank AbpStock exchange release – Major shareholder announcements20 August 2024 at 9.30 EET Norges Bank’s (The Central Bank of Norway) shareholding of Nordea Bank Abp’s shares and voting rights has decreased below the threshold of five percent, according to a notification Nordea received on 19 August 2024 under Chapter 9, Section 10 of the Securities Markets Act (SMA). The threshold was crossed on 16 August 2024. The total number of shares and voting rights in Nordea Bank Abp is 3,505,587,395. The total position of Norges Bank according to the notification: +-----------

Katalysen Ventures publishes report for the Second Quarter 2024

Katalysen Ventures AB (publ) hereby publishes the report for the Second Quarter 2024. The full report is available immediately as an attached document, and on the company's website. Below is a summary of the report.KPIs: · Number of ventures in portfolio at end of period: 26 (26) · Estimated portfolio market value at end of period: 147 MSEK (160 MSEK) · Cash resources in bank at end of period: 3.6 MSEK (1.2 MSEK) General Financial KPIs: Key Figures (Group*, TSEK) Q2 2024 Q2 2023 2023-01-01 2023-12-31Net sales

Nightingale Health receives additional regulatory approval for healthcare use from Health Sciences Authority in Singapore

Nightingale Health Plc Press release 20 August 2024 at 9:15 a.m. (EEST)   Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health has received additional regulatory approval from Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products. Nightingale Health announced earlier this year the first approval that covered the analysis of eight common clinically used biomarkers: total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides,

Notice of Special General Meeting

Hamilton, Bermuda, August 20, 2024 – Paratus Energy Services Ltd. (the "Company") announces that a Special General Meeting (“SGM”) will be held on September 5, 2024. As announced on 16 August 2024, the record date for voting at the SGM is set to August 16, 2024. A copy of the Notice of the SGM and associated information is attached to this press release. This information is subject to the disclosure requirements according to Section 5-12 of the Norwegian Securities Trading Act. For further information, please contact:Robert Jensen, CEORobert.Jensen@paratus-energy.com+47 958 26

Half-Yearly Report January - June 2024

A stable quarter despite subdued market conditions April – June 2024 · Net sales totaled SEK 29,470 (29,463) thousand, with a growth rate of 0.03%. Adjusted for currency effects, the decrease is -1%.  · Operating profit before depreciation and amortization (EBITDA) totaled SEK 5,272 (7,687) thousand. · Operating profit (EBIT) totaled SEK 2,517 (5,981) thousand. · Profit for the period totaled SEK 1,790 (15,219) thousand.  · Earnings per share totaled SEK 0.03 (0.23).  · Comprehensive income for the period totaled SEK 2,467 (16,843) thousand.  · Cash flow from

Repurchases of shares during week 33

Between 12 August and 16 August 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 120,329 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 150,000,000 that Attendo announced on 19 July 2024. The repurchase program, which runs between 22 July 2024 and 24 October 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU)

Finnish PropTech Startup Make a BIM Secures Funding to Accelerate Digitisation of Aging Building Stock

Helsinki, Finland – August 20, 2024 – Finnish PropTech startup Make a BIM has successfully raised pre-seed funding to scale its operations and further develop its automation technology. The funding round was led by Kiilto Ventures , with additional investments from Innovestor and angels from the Finnish Business Angels Network (FiBAN), including Kim Väisänen, Esa Kinnunen, and Teemu Jokinen.Addressing Europe’s urgent building challenge  The European Union faces a significant challenge: 97% of its buildings require upgrades to meet the goal of a decarbonized

Notice of Half-Year Financial Results

Faron Pharmaceuticals Ltd. (“Faron” or the “Company”)   Faron Pharmaceuticals Notice of Half-Year Financial Results   Company Announcement, 20 August 2024   TURKU, Finland – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, will report its unaudited half-year financial results for the six months ended June 30, 2024, on Tuesday, 27 August 2024.   A live hybrid briefing

There are no items matching the current filter
There are no more items matching the current filter
Back to top